NTRA
Natera, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 162 | 0 | 104.13M | $28.25B | +5 | −4 |
| Q1 2026 | 164 | +3 | 98.65M | $19.54B | +6 | −4 |
| Q4 2025 | 160 | 0 | 102.31M | $23.44B | +1 | — |
| Q3 2025 | 23 | +1 | 81.70M | $13.15B | +1 | −1 |
| Q2 2025 | 20 | -1 | 57.32M | $9.68B | — | −1 |
| Q1 2025 | 18 | 0 | 31.15M | $4.40B | — | — |
| Q4 2024 | 18 | 0 | 26.97M | $4.27B | — | — |
| Q3 2024 | 17 | -1 | 21.42M | $2.72B | — | −1 |
| Q2 2024 | 18 | — | 16.29M | $1.76B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 3.05M | — | $330.06M | 0.3% | n/c | 1 | SEC ↗ ×3 |
| 2 | Duquesne Family Office ✦ | 1.97M | — | $213.86M | 7.6% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.95M | — | $210.86M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 1.67M | — | $181.30M | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 1.32M | — | $142.63M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 1.15M | — | $124.03M | 0.2% | n/c | 1 | SEC ↗ |
| 7 | Marshall Wace ✦ | 958.38K | — | $103.78M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 8 | Wellington Management ✦ | 916.78K | — | $99.28M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 9 | AQR Capital Management ✦ | 651.52K | — | $70.55M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 10 | Point72 Asset Management ✦ | 561.94K | — | $60.85M | 0.2% | n/c | 1 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 528.81K | — | $57.27M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | ARK Investment Management ✦ | 415.34K | — | $44.98M | 0.4% | n/c | 1 | SEC ↗ |
| 13 | Capital World Investors ✦ | 396.42K | — | $42.93M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 331.98K | — | $35.95M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 216.50K | — | $23.44M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Soros Fund Management ✦ | 100.00K | — | $10.83M | 0.3% | n/c | 1 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 86.42K | — | $9.36M | 0.1% | n/c | 1 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 21.53K | — | $2.33M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 755 holders, 120.14M shares, $20.15B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.27K sh · $526,144
Director · 1.94K sh · $754,090
Director · 1.34K sh · $521,332
Director · 2.85K sh · $1.10M
Director · 2.30K sh · $889,271
Director · 390 sh · $150,263
Director · 110 sh · $42,946
Director · 2.32K sh · $904,069
Director · 1.29K sh · $502,598
Director · 2.73K sh · $1.06M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology